NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Secretome Therapeutics

Secretome Therapeutics

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://secretometherapeutics.com/

Last Round

Series A

May 27, 2026

Total Funding Raised

$31.75M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Secretome Therapeutics is a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells to address cardiovascular diseases and inflammatory conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologysecretome therapeuticsbiopharmaceuticalregenerative medicinedrug discoverycell therapybiologicssignaling moleculesclinical-stage biotechbioactive moleculestherapeutic candidatessecretomicscell-free therapybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Secretome Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Secretome Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Secretome Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 27, 2026
GrantMar 24, 2026
VC RoundNov 25, 2024
SeedOct 17, 2019

Secretome Therapeutics Investors

Notable investors and investment history

Secretome Therapeutics investors
InvestorRounds
HEST InvestmentsVC Round
RA Capital ManagementSeries A
Parent Project Muscular DystrophyGrant
Abell FoundationSeed
TEDCOSeed
UM VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 27, 2026

    $30M round led by RA Capital Management

  • May 22, 2026

    Grew 21% QoQ from 14 to 17 employees.

Secretome Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Secretome Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Secretome Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range18
Year Founded2022
Last FundingMay 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.